We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Upcoming OGD Initiatives Address Regulatory Science Priority List
Upcoming OGD Initiatives Address Regulatory Science Priority List
June 18, 2013
Upcoming pharmacokinetic studies, evaluations of drug product characterizations, and postmarketing assessments of therapeutic equivalence are among a handful of new initiatives being launched this year by the FDA’s Office of Generic Drugs (OGD) to address regulatory science priorities for generic drugs identified for 2013 as part of GDUFA.